MYGN Stock Analysis: Buy, Sell, or Hold?

MYGN - Myriad Genetics Inc

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
$5.99
-0.01 (-0.17%) ▼
5d: +10.31%
30d: +38.98%
90d: +30.5%
HOLD
MODERATE Confidence
Protect Your MYGN Gains
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026

Get Alerted When MYGN Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 HOLD - EXTENDED: MYGN is 13.7% above its trading range ($5.27). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
See Forward Earnings Fair Value & Price Prediction →

In-depth Analysis How we analyze

Valuation Analysis: MYGN is currently trading at $5.99, which is considered extended relative to its 30-day fair value range of $4.06 to $5.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 39.6) compared to its historical average (52.2). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, MYGN is showing sideways momentum. The price is approaching resistance at $6.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: MYGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $4.06 - $5.27
Company Quality Score 50/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 47.6%

Protect Your Profits

MYGN is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

  • BEARISH: Price significantly overextended (+13.7% above its trading range)
  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($6.25)

Trading Range Analysis

30-Day Trading Range $4.06 - $5.27
Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $4.39
Resistance Level $6.12
Current Trend Sideways
Technical data as of Jul 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 39.64
Wall Street Target $6.25 (+4.3%)
Revenue Growth (YoY) -20.8%
Profit Margin -41.3%
Valuation Discount vs History -8.8% cheaper
PE vs Historical 39.6 vs 52.2 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -8.8% (market-implied from PE analysis)
1-Year Target $5.46 (-9%)
2-Year Target $4.98 (-17%)
3-Year Target $4.54 (-24%)
3-Yr Target (if PE normalizes) (PE: 40→52) $5.98 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 39.6, Growth: 216.1%) $20.22 (+238%)
Base: (SPY PE: 21.8, Growth: 216.1%) $11.11 (+85%)
Bear: (PE: 18.5, Growth: 216.1%) $9.44 (+58%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 39.6 to 52.2
Stabilization Target: $7.89 (+31.7%)
PE Expansion Potential: +31.7%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: July 02, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Samraat S Raha BUY 40000 shares 2026-03-09
S. Louise Phanstiel BUY 48000 shares 2026-02-27
S. Louise Phanstiel BUY 50407 shares 2026-02-26

Unlock Insider Activity

See real-time buying/selling by company executives for MYGN.

Create Free Account

Already have an account? Log In

Top Rated Diagnostics & Research Stocks

Top-rated stocks in Diagnostics & Research by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
TMO
Thermo Fisher Scientific…
STRONG BUY
31 analysts
$599 64 BUY
EXAS
EXACT Sciences Corporati…
STRONG BUY
26 analysts
$106 65 BUY
DHR
Danaher Corporation
STRONG BUY
25 analysts
$242 64 BUY
GH
Guardant Health Inc
STRONG BUY
23 analysts
$144 61 BUY
NTRA
Natera Inc
STRONG BUY
21 analysts
$260 54 HOLD

Advanced MYGN Option Strategies

Professional options setups generated by AI based on today's MYGN price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for MYGN

MYGN Technical Chart MYGN Price Prediction MYGN Earnings Date MYGN Investment Advisor MYGN Fair Price Analyzer MYGN Options Advisor MYGN Options Chain MYGN Options Analysis MYGN Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals